Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06709573 · ClinicalTrials.gov registry record · Phase 4
Early Versus Late Adjunctive Vasopressin in Septic Shock
A Phase 4 study of Sepsis and Septic Shock, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06709573: Recruiting Phase 4 study of Sepsis and Septic Shock, sponsored by The Cleveland Clinic.
NCT06709573 is a Phase 4 study of Sepsis and Septic Shock that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 300 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06709573, a Phase 4 study of Sepsis and Septic Shock, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to create two distinct cohorts of patients reflecting different times of vasopressin initiation based on norepinephrine dose requirements. Secondarily, this study will evaluate the proportion of patients whose norepinephrine dose at the time of vasopressin initiation is within the specified range for the intervention arm they were randomized to. Other outcomes of evaluation will include adherence to the developed CDS technology and comparison of clinical outcomes between the two treatment arms.
Primary Outcome
The primary outcome is the norepinephrine-equivalent dose (in mcg/min) at the time of vasopressin initiation between patients who were randomized by CDS to early adjunctive vasopressin initiation compare to late adjunctive vasopressin initiation
Conditions Studied
Interventions
- DRUG vasopressin - early initiation
- DRUG vasopressin - standard initiation
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 4 |
What NCT06709573 shows while recruiting
NCT06709573 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which vasopressin - early initiation is the first listed.
NCT06709573 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06709573 about?
NCT06709573 is a clinical study titled "Early Versus Late Adjunctive Vasopressin in Septic Shock". The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to...
What is the current status of trial NCT06709573?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2025-04-29. Estimated completion is 2026-05-01.
What conditions does trial NCT06709573 study?
This clinical trial studies the following conditions: Sepsis, Septic Shock.
What interventions are being tested in trial NCT06709573?
The interventions under investigation include: vasopressin - early initiation (DRUG), vasopressin - standard initiation (DRUG).
Who is sponsoring clinical trial NCT06709573?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06709573 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06709573's enrollment target sits among peer trials
300 34th of 90 higher than 54 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
The PASTDUe Nutrition Ecosystem Project (PASTDUe)
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Nebulized Bronchodilators on Heart Rate
COMPLETED · Phase 4
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI